Focal Segmental Glomerulosclerosis (FSGS) Recruiting Phase 0 Trials for Rituximab (DB00073)

Also known as: Focal Glomerulosclerosis / Glomerulosclerosis, Focal / Focal Segmental Glomerulosclerosis / Glomerulosclerosis, Focal Segmental / APOL1-mediated focal segmental glomerulosclerosis / Focal & segmental glomerulosclerosis / Focal glomerular sclerosis (disorder) / Focal segmental glomerulosclerosis (disorder)

IndicationStatusPhase
DBCOND0038485 (Focal Segmental Glomerulosclerosis (FSGS))Recruiting0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03763643PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantPrevention